FROM THE START

  • 2012

    DISCOVERY

    of effective Microbiome Therapeutics following fecal transplant studies at AMC in Amsterdam (Vrieze et al., 2012)

  • 2013

    INTELLECTUAL PROPERTY

    on Microbiota-based concepts for prevention and early treatment of T2D.

  • 2014

    INCEPTION CAELUS

    from Academic Medical Center (AMC) in Amsterdam and Wageningen University in the Netherlands.

  • 2014-2015

    PROOF OF CONCEPT

    of the lead product E. hallii in a clinical trial in Metabolic Syndrome showing increased insulin sensitivity. This implies reduced risk of developing diabetes.

  • 2016-2019

    DISCOVERY STUDIES

    based on FMT resulting in new leads in Diabetes, Cachexia and Auto-immune diseases

  • -

    PIPELINE

    Development of a broad range of microbiota based products and innovative formulations for prevention and early treatment.